Prospective Study of Patients Switched from arilocumab to evolocumab(SWITCH From Arilocumab To Evolocumab study: switch fate Study)

INTERVENTION:

Before switching from 75 mg, 150 mg arilocumab to 140 mg, 420 mg evolocumab, and 6 months and 1 year after the switch. Evolocumab 140mg, 420mg continued: at start of intervention, 6 months after intervention, 1 year after intervention

CONDITION:

Hyperlipidemia

PRIMARY OUTCOME:

Lipid profile (TC,TG,HDL‐C, Friedewald LDL‐C,small dense LDL,IDL,Lp(a),LDL oxidation ability,LDL stability,oxidized LDL,3%PAGE,Agarose gel electrophoresis,electronegative LDL),apo protein, apoE phenotype

SECONDARY OUTCOME:

Cr, BUN, Urinal analysis, GOT, GPT, CK, (following in the case of DM), fasting blood glucose, HbA1, hematologic changes such as thrombocytopenia, etc., early‐phase and late‐phase of allergic reaction to PCSK9 inhibitor.

INCLUSION CRITERIA: